This indicates that safety signals are more visible in pooled short-term RCTs, while long-term adherence and the risks of weight rebound or metabolic withdrawal post-discontinuation remain difficult to quantify reliably in existing studies
The FDA has approved a handful of GLP-1 and dual GIP/GLP-1 medications for chronic weight management
For many, cost and insurance worries have blocked the path to achieving their weight loss objectives
Tirzepatide is the leading choice for weight loss, demonstrating average reductions of 12-17% in body weight, offering additional benefits for blood sugar control, but raises potential safety concerns
For patients who want to transition from a compounded product to an FDA-approved one, both clinicians cautioned that the process isnt always straightforward, as it may not be clear what dose a patient on a compounded product had been taking
This pattern mirrors what researchers see with semaglutide GI side effects and tirzepatide GI side effects